Filing Details

Accession Number:
0000903423-15-000173
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-02 15:45:05
Reporting Period:
2015-03-02
Filing Date:
2015-03-02
Accepted Time:
2015-03-02 15:45:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080014 Theravance Inc THRX Pharmaceutical Preparations (2834) 943265960
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1131399 Plc Glaxosmithkline 980 Great West Road
Brentford Middlesex, X0 TW8 9GS
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-02 92,674 $1,673,692.44 31,673,853 No 4 P Indirect By Corporation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Corporation
Footnotes
  1. Common stock purchased pursuant to the right of GlaxoSmithKline LLC ("GSK LLC") under Section 2.1(d)(ii) and 2.1(d)(v) of the Amended and Restated Governance Agreement by and among Theravance, Inc. (the "Issuer"), GSK LLC, Glaxo Group Limited and GlaxoSmithKline plc dated as of June 4, 2004, as amended. Pursuant to Section 2.1(d)(ii), GSK LLC has the right to purchase from the Issuer, on a quarterly basis, sufficient shares of common stock to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity. Pursuant to Section 2.1(d)(v), GSK LLC has the right to purchase from the Issuer sufficient shares of common stock to maintain its ownership percentage in the Issuer as a result of the conversion of certain of the Issuer's convertible indebtedness.
  2. Shares of Common Stock are held of record by Glaxo Group Limited, an indirect wholly owned subsidiary of GlaxoSmithKline plc.